Literature DB >> 22437237

Nomenclature for immune correlates of protection after vaccination.

Stanley A Plotkin1, Peter B Gilbert.   

Abstract

Identification of immune correlates of protection after vaccination is an important part of vaccinology for both theoretical and practical reasons. The terminology and definition of correlates have been confusing, because different authors have used variable terms and concepts. Here, we attempt to give precision to the field by defining 3 terms: correlate of protection (CoP), mechanistic correlate of protection (mCoP), and nonmechanistic correlate of protection (nCoP). A CoP is a marker of immune function that statistically correlates with protection after vaccination that may be either an mCoP, which is a mechanistic cause of protection, or an nCoP, which does not cause protection but nevertheless predicts protection through its (partial) correlation with another immune response(s) that mechanistically protects.

Mesh：

Substances：

Year:  2012        PMID： 22437237      PMCID： PMC3348952          DOI： 10.1093/cid/cis238

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

Review 1.  Immunologic correlates of protection induced by vaccination.

Authors:  S A Plotkin
Journal:  Pediatr Infect Dis J       Date:  2001-01       Impact factor: 2.129

2.  Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Authors:  Peter B Gilbert; Michael G Hudgens; Julian Wolfson
Journal:  Int J Biostat       Date:  2011-09-20       Impact factor: 0.968

Review 3.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

4.  Augmented designs to assess immune response in vaccine trials.

Authors:  Dean Follmann
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

Review 5.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

6.  A framework for assessing immunological correlates of protection in vaccine trials.

Authors:  Li Qin; Peter B Gilbert; Lawrence Corey; M Juliana McElrath; Steven G Self
Journal:  J Infect Dis       Date:  2007-10-02       Impact factor: 5.226

7.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

Review 8.  Immunity and correlates of protection for rotavirus vaccines.

Authors:  Manuel A Franco; Juana Angel; Harry B Greenberg
Journal:  Vaccine       Date:  2006-01-17       Impact factor: 3.641

Review 9.  Meningococcal surrogates of protection--serum bactericidal antibody activity.

Authors:  Ray Borrow; Paul Balmer; Elizabeth Miller
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

10.  Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.

Authors:  Adriana Weinberg; Jane H Zhang; Michael N Oxman; Gary R Johnson; Anthony R Hayward; Michael J Caulfield; Michael R Irwin; James Clair; Jeffrey G Smith; Harold Stanley; Rocio D Marchese; Ruth Harbecke; Heather M Williams; Ivan S F Chan; Robert D Arbeit; Anne A Gershon; Florian Schödel; Vicki A Morrison; Carol A Kauffman; Steve E Straus; Kenneth E Schmader; Larry E Davis; Myron J Levin
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226
  10 in total
  144 in total

1.  Mining the mechanisms of an HIV vaccine.

Authors:  Stanley A Plotkin; Harriet L Robinson; Miles P Davenport
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

Review 2.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

3.  Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Authors:  Holly E Janes; Kristen W Cohen; Nicole Frahm; Stephen C De Rosa; Brittany Sanchez; John Hural; Craig A Magaret; Shelly Karuna; Carter Bentley; Raphael Gottardo; Greg Finak; Douglas Grove; Mingchao Shen; Barney S Graham; Richard A Koup; Mark J Mulligan; Beryl Koblin; Susan P Buchbinder; Michael C Keefer; Elizabeth Adams; Chuka Anude; Lawrence Corey; Magdalena Sobieszczyk; Scott M Hammer; Peter B Gilbert; M Juliana McElrath
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

4.  Calibration weighted estimation of semiparametric transformation models for two-phase sampling.

Authors:  Youyi Fong; Peter Gilbert
Journal:  Stat Med       Date:  2015-02-04       Impact factor: 2.373

5.  Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.

Authors:  Peter B Gilbert; Ying Huang
Journal:  Epidemiol Methods       Date:  2016-01-23

6.  Cellular immune correlates analysis of an HIV-1 preexposure prophylaxis trial.

Authors:  Peter J Kuebler; Megha L Mehrotra; J Jeff McConnell; Sara J Holditch; Brian I Shaw; Leandro F Tarosso; Kaitlyn S Leadabrand; Jeffrey M Milush; Vanessa A York; Rui André Saraiva Raposo; Rex G Cheng; Emily M Eriksson; Vanessa McMahan; David V Glidden; Stephen Shiboski; Robert M Grant; Douglas F Nixon; Esper G Kallás
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

Review 7.  Recent developments in clinical trial designs for HIV vaccine research.

Authors:  Laura Richert; Edouard Lhomme; Catherine Fagard; Yves Lévy; Geneviève Chêne; Rodolphe Thiébaut
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 8.  Modeling HIV vaccine trials of the future.

Authors:  Peter B Gilbert; Ying Huang; Holly E Janes
Journal:  Curr Opin HIV AIDS       Date:  2016-11       Impact factor: 4.283

Review 9.  The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.

Authors:  Abdulmohammad Pezeshki; Inna G Ovsyannikova; Brett A McKinney; Gregory A Poland; Richard B Kennedy
Journal:  Expert Rev Vaccines       Date:  2019-02-11       Impact factor: 5.217

Review 10.  Applications and challenges of multivalent recombinant vaccines.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.